LYLu Yue

Lu Yue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lu Yue has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Fang Zhou

    Department of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China

    5 shared publications
  • Ruyong Yao

    Department of Central Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, People’s Republic of China

    4 shared publications
  • Jing Lv

    Department of Oncology, Affiliated Hospital of Medical College Qingdao University Qingdao China

    3 shared publications
  • Jun Liang

    Qingdao University

    3 shared publications
  • Tao Qin

    The Third Clinical School of Medical Science, Qingdao University, Qingdao Municipal Hospital

    3 shared publications
  • Wensheng Qiu

    Department of Oncology, Affiliated Hospital of Medical College, Qingdao University, Qingdao, China

    3 shared publications

Latest Publications

  • Open Access

    Orchestrating cancer stem cell plasticity: deubiquitinases as key regulators of EMT and metabolic rewiring

    by Tao Qin, Yupeng Wang, Minhao Li, Qian Liu, Lu Yue, Shuzhen Liang, Duoping Sun

    Cancer stem cells (CSCs) drive tumor relapse, metastasis, and multidrug resistance, primarily attributed to their profound phenotypic plasticity. This plasticity largely depends on the dynamic interplay between the epithelial-mesenchymal transition (EMT) program and metabolic reprogramming. However, the molecular mechanisms coordinating these processes remain incompletely elucidated. Emerging evidence suggests that deubiquitinating enzymes (DUBs) may participate in regulating this complex crosstalk. This review systematically elaborates on the functional roles of DUBs in maintaining CSC characteristics within malignancies, exploring how they regulate CSC fate by modulating developmental signaling cascades (Wnt/β-catenin, Hedgehog (Hh), Notch, and TGF-β). By preventing the proteasomal degradation of key transcription factors, DUBs simultaneously drive EMT and coordinate metabolic reprogramming to meet the energetic demands of migrating CSCs. Furthermore, we emphasize the bidirectional feedback loops between EMT-TFs and DUBs, which cooperatively amplify stemness. Finally, selective targeting of the DUB-EMT-metabolism axis may represent a potential strategy for dismantling CSC plasticity and improving responses to anticancer therapies.

  • Open Access

    Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy

    by Yan Zhu, Chun Yan, Xiaofei Wang, Zhijian Xu, Jianjian Lv, Xiaomei Xu, Wenjun Yu, Mi Zhou, Lu Yue

    Although immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment, the accuracy of predictive biomarkers for ICI outcomes, such as PD-L1, TMB (tumor mutation burden) or MMR (mismatch repair) deficiency, have not been satisfactory. ARID family members are essential for maintaining the basic process of genomic stability and may serve as novel biomarkers for ICI therapy. A total of 1660 cancer patients who received ICI therapy were included in this pan-cancer analysis. The basic information and TMB values of each patient were collected. Survival analysis based on the Kaplan-Meier (KM) method was performed to explore the relationships between mutations in ARID family members and prognosis in pan-cancer as well as cancer subtypes. Genetic alterations in ARID1A (12%), ARID1B (5%), ARID2 (6%) and ARID5B (2.6%) were identified in multiple cancer types. Patients harboring mutated ARID family members benefited more from ICI therapy (P = .0003). Mutated ARID1A (P = .01), ARID1B (P = .0097) and ARID2 (P = .0054) all serve as compelling biomarkers in predicting the prognosis of ICI treatment. In addition, members of the ARID family were found to be strongly related to the abundance of CD4 + T cells and CD8 + T cells, the expression of PD-L1 and the TMB value in various cancers. Specifically, members of the ARID family could serve as novel biomarkers in multiple malignancies, especially gastrointestinal cancers. ARID family members serve as novel biomarkers for ICI therapy in malignancies. Testing the genomic status of ARID family members could help identify the definite subpopulation that benefits most from ICI treatment. Abbreviations: AT-rich interactive domain (ARID)Switch/sucrose nonfermenting (SWI/SNF)Non-small cell lung cancer (NSCLC)Immune checkpoint inhibitors (ICIs)Tumor microenvironment (TME)Programmed death-ligand 1 (PD-L1)Tumor mutational burden (TMB)


  • Open Access

    Prognostic value of eight immune gene signatures in pancreatic cancer patients

    by Wenting Wang, Zhijian Xu, Ning Wang, Ruyong Yao, Tao Qin, Hao Lin, Lu Yue

    Background: Pancreatic cancer is one of the most common malignant tumors of the digestive tract, and it has a poor prognosis. Traditional methods are not effective to accurately assess the prognosis of patients with pancreatic cancer. Immunotherapy is a new promising approach for the treatment of pancreatic cancer; however, some patients do not respond well to immunotherapy, which may be related to tumor microenvironment regulation. In this study, we use gene expression database to mine important immune genes and establish a prognostic prediction model for pancreatic cancer patients. We hope to provide a feasible method to evaluate the prognosis of pancreatic cancer and provide valuable targets for pancreatic cancer immunotherapy. Results: We used univariate COX proportional hazard regression analysis, the least absolute shrinkage and selection operator, and multivariate COX regression analysis to screen 8 genes related to prognosis from the 314 immune-related genes, and used them to construct a new clinical prediction model in the TCGA pancreatic cancer cohort. Subsequently, we evaluated the prognostic value of the model. The Kaplan–Meier cumulative curve showed that patients with low risk scores survived significantly longer than patients with high risk scores. The area under the ROC curve (AUC value) of the risk score was 0.755. The univariate COX analysis showed that the risk score was significantly related to overall survival (HR 1.406, 95% CI 1.237–1.598, P < 0.001), and multivariate analysis showed that the risk score was an independent prognostic factor (HR 1.400, 95% CI 1.287–1.522, P < 0.001). Correlation analysis found that immune genes are closely related to tumor immune microenvironment. Conclusions: Based on the TCGA-PAAD cohort, we identified immune-related markers with independent prognostic significance, validated, and analyzed their biological functions, to provide a feasible method for the prognosis of pancreatic cancer and provide potentially valuable targets for pancreatic cancer immunotherapy.


  • Open Access

    Prognostic value of eight immune gene signatures in pancreatic cancer patients

    by Wenting Wang, Zhijian Xu, Ning Wang, Ruyong Yao, Tao Qin, Hao Lin, Lu Yue

    BackgroundPancreatic cancer is one of the most common malignant tumors of the digestive tract, and it has a poor prognosis. Traditional methods are not effective to accurately assess the prognosis of patients with pancreatic cancer. Immunotherapy is a new promising approach for the treatment of pancreatic cancer; however, some patients do not respond well to immunotherapy, which may be related to tumor microenvironment regulation. In this study, we use gene expression database to mine important immune genes and establish a prognostic prediction model for pancreatic cancer patients. We hope to provide a feasible method to evaluate the prognosis of pancreatic cancer and provide valuable targets for pancreatic cancer immunotherapy.ResultsWe used univariate Cox proportional hazard regression analysis, the least absolute shrinkage and selection operator (LASSO), and multivariate COX regression analysis to screen 8 genes related to prognosis from the 314 immune-related genes, and used them to construct a new clinical prediction model in the TCGA pancreatic cancer cohort. Subsequently, we evaluated the prognostic value of the model. The Kaplan–Meier cumulative curve showed that patients with low risk scores survived significantly longer than patients with high risk scores. The area under the ROC curve (AUC value) of the risk score was 0.755.The univariate COX analysis showed that the risk score was significantly related to overall survival (OS) (HR = 1.406, 95% CI = 1.237 ~ 1.598, P <0.001), and multivariate analysis showed that the risk score was an independent prognostic factor (HR = 1.400 95% CI = 1.287 ~ 1.522, P <0.001). Correlation analysis found that immune genes are closely related to tumor immune microenvironment.ConclusionsBased on the TCGA-PAAD cohort, we identified immune-related markers with independent prognostic significance, validated, and analyzed their biological functions, to provide a feasible method for the prognosis of pancreatic cancer and provide potentially valuable targets for pancreatic cancer immunotherapy.

    • 1 January 2020
      • Vol. 13  (5) , 934-943

    Myocyte-specific enhancer factor 2D promotes tumorigenesis and progression in tongue squamous cell carcinoma

    by Yang Liu, Wenjun Yu, Yan Zhu, Zhenni Sun, Xingang Huang, Jianhua Zhou, Ruyong Yao, Qian Zhang, Jianzhong Qiu, Lu Yue

    Tongue squamous cell carcinoma (TSCC) ranks as one of the most common cancers worldwide and has a poor prognosis. Myocyte-specific enhancer factor 2 (MEF2D) has recently been considered as a novel factor involved in cancer development. In the present study, the function and underlying mechanism of MEF2D in TSCC were investigated. The levels of MEF2D mRNA and protein were determined in human TSCC samples by RT-qPCR and western blot, respectively. The interaction between MEF2D expression and clinicopathologic features was evaluated by IHC and analysis of clinical information. MEF2D-mediated effects on proliferation, migration, and invasion were explored in TSCC cells after transfection with MEF2D-siRNA. The results showed higher expression of MEF2D at both the mRNA and protein levels in TSCC carcinoma tissues than in paracarcinoma tissues. Furthermore, high expression of MEF2D was positively correlated with tumor differentiation and lymphatic metastasis. MEF2D knocked down TSCCA cells also had reduced proliferative, migratory, and invasive abilities compared to those of control cells. Together, these data confirmed that knockdown of MEF2D might suppress the growth and metastasis of TSCC, which further indicated that MEF2D might serve as a therapeutic target for TSCC treatment.


  • Both high expression of nucleophosmin/B23 and CRM1 predicts poorer prognosis in human gastric cancer

    by Fang Zhou, Ercheng Chen, Dong You, Yipeng Song, Zhenni Sun, Lu Yue

    Nucleophosmin/B23 and CRM1 are molecular markers which play an important role in tumorigenesis and tumor progression in gastric cancer (GC). However, the association between the two remains unclear. This study evaluated the expression and the correlation of B23 and CRM1 in GC. B23 and CRM1 expression in GC and adjacent noncancerous tissues (ANCT) of gastrectomy specimens from 131 GC patients was measured by immunohistochemistry. Positive expression rates of B23 and CRM1 were significantly higher in GC tissues than in ANCT. The high expression rates of B23 and CRM1 were significantly higher in patients with more advanced tumor stages and distant metastasis (all p < 0.05). Only high expression of CRM1was correlated with positive Her2 status (p = 0.01). B23 expression was positively correlated with CRM1expression in GC tissues (p = 0.038). Univariate analysis showed that TNM stage (p = 0.0001), metastasis (p = 0.027), B23 (p = 0.0111), and CRM1 expression (p = 0.0019) were significant risk factors affecting overall survival. Both high expression of B23 and CRM1 in GC patients suggests poor prognosis, co-expression of the two (p = 0.043) even worse. Cox multivariate analysis showed that positive B23 (p = 0.0231) and CRM1 (p = 0.0048) expression were both independent prognostic factors that negatively correlated with survival. We revealed the co-expression of B23 or CRM1 in GC. The expression levels of B23 or CRM1 were closely related to poor prognosis in GC, and both B23 or CRM1 were independent risk factor.


  • Open Access

    MiR‐200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1

    by YaSai Yao, Jian Hu, Zan Shen, RuYong Yao, ShiHai Liu, Yong Li, Hui Cong, XinGang Wang, WenSheng Qiu, Lu Yue

    MicroRNAs (miRNAs) have been identified as important post‐transcriptional regulators involved in various biological and pathological processes of cells. In the present study, we investigated the roles and mechanisms of miR‐200b in human breast cancer (BC). MiR‐200b expression was carried out by qRT‐PCR in human BC cell lines and clinical samples and the prognostic potential of miR‐200b expression was further evaluated. In vitro, effects of miR‐200b on BC cell proliferation, apoptosis and cell cycle distribution were tested by CCK‐8 kit, flow cytometric analysis respectively. Luciferase assay and Western blot analysis were performed to validate the potential targets of miR‐200b after the preliminary screening by employing open access software. We found that miR‐200b was significantly down‐regulated in both BC tissues and cell lines. The low expression of miR‐200b was correlated with late TNM stage, negative oestrogen receptor and positive HER‐2 status. Multivariate analysis showed that miR‐200b expression was an independent prognostic predictor for BC patients. Integrated analysis identified Sp1 as a direct and functional target of miR‐200b. Knockdown of Sp1 inhibited cell proliferation, induce apoptosis and act on cell cycle resembling that of miR‐200b high expression. Our data demonstrates that miR‐200b has potential to serve as prognostic biomarker and tumour suppressor for BC patients. As a direct and functional target of miR‐200b, Sp1 and miR‐200b both could be an exciting target for BC treatment strategy.


  • MOR1 Expression in Gastric Cancer: A Biomarker Associated With Poor Outcome

    by Ya‐Sai Yao, Ru‐Yong Yao, Li‐Kun Zhuang, Wei‐Wei Qi, Jing Lv, Fei Zhou, Wen‐Sheng Qiu, Lu Yue

    Background: At present, the expression of MOR1 and its function in gastric cancer remains unclear with evidence suggesting that it is to be involved in tumor progression and metastasis. The study was to assess the clinicopathologic relevance and prognostic value of MOR1 expression in gastric cancer.Methods: Real‐time quantitative RT‐PCR and immunohistochemical staining were used to detect MOR1 expression in primary gastric cancerous surgical specimens and adjacent nontumorous tissues.Results: High MOR1 expression was detected in cancerous tumor compared with their adjacent nontumorous tissues. In addition, the chi‐square test revealed that high MOR1 expression was significantly correlated with depth of invasion (p= 0.006), lymph node metastasis (p= 0.001), distant metastasis (p= 0.017), and TNM staging (p= 0.027). Moreover, Kaplan–Meier analysis revealed a significant association between MOR1 expression and overall survival. High expression of MOR1 was identified as an independent and significant predictor gene of reduced postoperative survival.Conclusion: We conclude that MOR1 expression may be a useful biomarker for better prediction of the clinical outcome and management of gastric cancer patients.


  • Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma

    by Jing Lv, Ya-Sai Yao, Fei Zhou, Li-Kun Zhuang, Ru-Yong Yao, Jun Liang, Wen-Sheng Qiu, Lu Yue

    HER2 amplification and/or expression occurs in gastric carcinoma (GC), but the role of HER2 in the prognosis of GC remains unclear. The dysregulation of transforming acidic coiled coil 1 (TACC1), a downstream gene of HER2, is thought to be involved in the development of GC. The aim of this study was to investigate the role and relationship of HER2 and TACC1 in GC. The expression of HER2 and TACC1 was analyzed using immunohistochemistry on 129 primary resected GC patients, and HER2 amplification was additionally determined by FISH. The data on clinicopathological features and relevant prognostic factors in these patients were analyzed. The expression (3+, 2+ and 1+) and the amplification of HER2 was observed in 57 cases (44.2 %) and 25 cases (19.4 %), respectively, and the correlation between HER2 expression and amplification was strong (p HER2 positive. A total 62 (48.1 %) GC tissues showed positive cytoplasmic staining of TACC1. There was a significant and positive association between TACC1 and HER2. HER2 positive was significantly associated with TNM stage (p = 0.019), and TACC1 expression was significantly associated with lymph node metastasis (p = 0.004) and TNM stage (p = 0.004). TNM stage, TACC1 expression and co-positive of both HER2 and TACC1 were independent prognostic factors. TACC1 expression is an independent prognostic indicator of GC. The correlation between TACC1 expression and HER2-positive status indicated a possible synergistic regulation of the two molecules and co-positive of both HER2 and TACC1 maybe a more valuable prognostic marker.


  • CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas

    by Fang Zhou, Wensheng Qiu, Ruyong Yao, Jinyu Xiang, Xiaoxiao Sun, Shihai Liu, Jing Lv, Lu Yue

    Gastric cancer (GC) is a highly aggressive malignant tumor. Its high mortality rate prompts the urgent need for novel therapeutic agents. The aim of this study is to detect the expression of CRM1 in GC, which has not been reported to date. The expression of CRM1 in GC and adjacent noncancerous tissues (ANCT) of gastrectomy specimens from 120 GC patients was measured by immunohistochemistry. In addition, correlations between the CRM1 staining and the clinicopathologic features as well as survival were analyzed. Positive expression rates of CRM1 in GC and ANCT were 57.8 and 6.7 %, respectively. High expression of CRM1 was significantly associated with increased serum level of carcinoma embryonic antigen (CEA, P = 0.02) but not associated with that of carbohydrate antigen 19–9 (P = 0.38). CRM1 levels were correlated with more advanced tumor stages (P = 0.01), positive Her2 status (P = 0.01), and distant metastasis (P = 0.02). Univariate analysis showed that CEA (P = 0.0076), TNM stage (P = 0.0001), metastasis (P = 0.027), and CRM1 expression (P = 0.0019) were significant risk factors affecting overall survival of GC patients. The multivariate analysis indicated that the CRM1 was an independent indicator for GC survival (P = 0.0048). The current results indicated that CRM1 expressed in a subpopulation of GC with aggressive behavior and could serve as a prognosis marker for poor outcome.